Renal sodium glucose cotransporter 2 inhibitors as a novel therapeutic approach to treatment of type 2 diabetes: Clinical data and mechanism of action.
Renal sodium glucose cotransporter 2 inhibitors as a novel therapeutic approach to treatment of type 2 diabetes: Clinical data and mechanism of action.
复制标题
DOI：
10.1111/jdi.12214
复制
发表时间：
2014-05-04
影响因子：
3.2
通讯作者：
Inagaki N
中科院分区：
文献类型：
--
作者：
Fujita Y;Inagaki N
2型糖尿病的特征在于胰腺β细胞的胰岛素分泌受损和/或靶组织对胰岛素的反应降低。良好的血糖控制可延迟微血管和大血管并发症的发生并减缓其进展。虽然有许多降糖药在临床使用，只有大约一半的2型糖尿病患者实现血糖控制，不良副作用往往妨碍治疗的药物治疗。需要新的治疗方案来帮助克服这些困难。钠葡萄糖协同转运蛋白2（SGLT 2）抑制剂最近已被开发为治疗2型糖尿病的一种新的潜在治疗选择。这些药物通过抑制肾脏葡萄糖再摄取降低血糖浓度，不依赖于胰岛素分泌和胰岛素作用，从而降低低血糖风险。单药治疗和联合治疗的临床试验数据表明，SGLT 2抑制剂具有降糖作用，还可减轻体重。一项随访研究显示了这些效果的长期疗效和持久性。SGLT 2抑制剂具有逆转葡萄糖毒性、改善胰岛素抵抗、血压和血脂的潜力。现有数据表明耐受性良好。然而，临床医生应该根据已经报告的和/或意外的副作用谨慎处方这些药物。需要更多的进一步研究和更长期的临床使用数据，以将这些药物用于2型糖尿病的标准治疗。
Type 2 diabetes is characterized by impaired insulin secretion from pancreatic β‐cells and/or reduced response of target tissues to insulin. Good glycemic control delays the development and slows the progression of micro‐ and macrovascular complications. Although there are numerous glucose‐lowering agents in clinical use, only approximately half of type 2 diabetic patients achieve glycemic control, and undesirable side‐effects often hamper treatment in those treated with the medications. There is a need for novel treatment options that can help overcome these difficulties. Sodium glucose cotransporter 2 (SGLT2) inhibitors have recently been developed as a novel potential therapeutic option for the treatment of type 2 diabetes. These drugs lower the plasma glucose concentration through inhibition of glucose reuptake in the kidney, independent of insulin secretion and insulin action, with a consequent lower risk of hypoglycemia. The data of clinical trials with monotherapy as well as combination therapy show that SGLT2 inhibitors have a blood glucose‐lowering effect and also reduce bodyweight. A follow‐up study shows long‐term efficacy and the durability of these effects. SGLT2 inhibitors have the potential to reverse glucose toxicity, and to improve insulin resistance, blood pressure and lipid profile. The available data suggest a good tolerability profile. However, clinicians should carefully prescribe these drugs in light of already reported and/or unexpected side‐effects. Further studies in larger numbers and longer‐term clinical use data are required to place these agents in standard treatment of type 2 diabetes.
登录
查看更多内容
影响因子：
2.9
作者：
Clar C;Gill JA;Court R;Waugh N
通讯作者：
Waugh N
影响因子：
168.9
作者：
Bailey, Clifford J.;Gross, Jorge L.;List, James F.
通讯作者：
List, James F.
影响因子：
7.7
作者：
Abdul-Ghani MA;DeFronzo RA;Norton L
通讯作者：
Norton L
DOI：
10.2147/dddt.s48937
发表时间：
2013
期刊：
Drug design, development and therapy
影响因子：
--
作者：
Dietrich E;Powell J;Taylor JR
通讯作者：
Taylor JR
达帕格列非佐以二甲双胍治疗二甲双胍控制不佳的 2 型糖尿病：一项为期 102 周的随机、双盲、安慰剂对照试验。
影响因子：
9.3
作者：
Bailey CJ;Gross JL;Hennicken D;Iqbal N;Mansfield TA;List JF
通讯作者：
List JF